GLP-1 drugs may quiet cravings by reshaping brain reward and satiety signals, reducing food-seeking drive and binge-like eating, while long-term effects remain unclear.
|Videos|December 29, 2021
Mapping the Mind
Author(s)Amit Etkin, MD, PhD
How can we enhance our understanding of the human brain?
Advertisement
In this Mental Health Minute video, Amit Etkin, MD, PhD, cofounder and CEO of Alto Neuroscience and professor of psychiatry and behavioral sciences at Stanford University, discusses the results of a recent
Dr Etkin is cofounder and CEO of
Advertisement
Related to this article
Breakthrough Alzheimer updates: UK adaptive platform trial tests repurposed drugs, new phase 2/3 therapies advance, and sleep disruption emerges as a treatable risk factor.
Behind the scenes at a psychiatry conference, Gus Alva, MD, DFAPA, and Erin Crown share practical insights on burnout, industry, and emerging treatments—turning continuing education into better patient outcomes.
Phase 2 trial shows daridorexant boosts pediatric insomnia sleep time up to 50 minutes, including ADHD/ASD patients, with strong safety and phase 3 plans.
New automated connectomics maps synapses across circuits, revealing how inhibitory neuron subtypes shape decision-making and may explain circuit dysfunction in psychiatric disorders.
FDA aligns with Cognition on a phase 3 zervimesine trial for Lewy body dementia, testing 100 mg daily for 9 months to target hallucinations.
Sleep disruption fuels Alzheimer risk via apnea, fragmentation, and inflammation; improving consolidated sleep, medication review, and sleep-specialist teamwork may protect cognition.
UK AD-SMART platform trial speeds Alzheimer disease treatment discovery by testing multiple repurposed drugs at once across NHS sites, aiming to protect memory and quality of life.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Daridorexant, Orexin Receptor Agonist, Shows Positive Results in Pediatric Insomnia
2
Food Noise and GLP-1 Drugs: What Research Reveals About Motivation and Appetitive Drive
3
Synapse-Level Mapping Could Reveal How Disrupted Brain Circuits Lead to Psychiatric Disorders
4
Dementia Pipeline Update: Phase 2 and 3 Developments in Alzheimer Disease and Lewy Body Dementia
5